VEGFA and colorectal cancer: Studies in colorectal cancer have demonstrated that anti-VEGF (vascular endothelial growth factor) therapy (e.g., bevacizumab) can transiently “normalize” the aberrant vascular network by pruning immature vessels and reinforcing the remaining ones, thereby improving perfusion, alleviating hypoxia, and significantly enhancing the delivery and efficacy of concomitant chemotherapeutic agents [52,53].